ConductScience.org, home

Comparison · NCT02611765-52193ce2

Enhanced Therapy vs Standard Therapy: Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Enhanced Therapy vs Standard Therapy: Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold). Trial comparisons, record NCT02611765-52193ce2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02611765-52193ce2

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.9310.780.981wilson
Risk in group 20.80.6410.9wilson
Risk difference, group 1 minus group 20.131-0.04960.298newcombe hybrid score
Risk ratio, group 1 over group 21.160.961.41log
Odds ratio, group 1 over group 23.380.64317.7log
Number needed to treat, for one more participant with the outcome on Enhanced Therapy than on Standard Therapy7.63from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Enhanced Therapy
Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)~Enhanced therapy: Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
2729OG000
Group 2Standard TherapyA single intramuscular injection of 2.4 million units of benzathine penicillin G~Standard therapy: A single dose of intramuscular 2.4 million units of benzathine penicillin G2835OG001

Outcome

Type
PRIMARY
Title
Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold)
Description
Number of participants who achieve treatment success. Loss to follow-up was assumed to be a failure.
Time frame
12 months
Population

Source ClinicalTrials.gov

Trial

Title
Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
NCT number
NCT02611765
Phases
PHASE4
Conditions
Syphilis
Interventions
Benzathine penicillin G intramuscular 7.2 million units, Benzathine penicillin G intramuscular 2.4 million units
Lead sponsor
Baylor College of Medicine
Results first posted
2016-04-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02611765-52193ce2